Search Results
You are looking at 1 - 2 of 2 items for
- Author: Francesco Raimondi x
- Refine by access: All content x
Search for other papers by Teresa Ramone in
Google Scholar
PubMed
Search for other papers by Cristina Romei in
Google Scholar
PubMed
Search for other papers by Raffaele Ciampi in
Google Scholar
PubMed
Search for other papers by Roberta Casalini in
Google Scholar
PubMed
Search for other papers by Angelo Valetto in
Google Scholar
PubMed
Search for other papers by Veronica Bertini in
Google Scholar
PubMed
Search for other papers by Francesco Raimondi in
Google Scholar
PubMed
Search for other papers by Anthony Onoja in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed
Search for other papers by Clara Ugolini in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Somatic copy number alterations (SCNA) involving either a whole chromosome or just one of the arms, or even smaller parts, have been described in about 88% of human tumors. This study investigated the SCNA profile in 40 well-characterized sporadic medullary thyroid carcinomas by comparative genomic hybridization array. We found that 26/40 (65%) cases had at least one SCNA. The prevalence of SCNA, and in particular of chromosome 3 and 10, was significantly higher in cases with a RET somatic mutation. Similarly, SCNA of chromosomes 3, 9, 10 and 16 were more frequent in cases with a worse outcome and an advanced disease. By the pathway enrichment analysis, we found a mutually exclusive distribution of biological pathways in metastatic, biochemically persistent and cured patients. In particular, we found gain of regions involved in the intracellular signaling and loss of regions involved in DNA repair and TP53 pathways in the group of metastatic patients. Gain of regions involved in the cell cycle and senescence were observed in patients with biochemical disease. Finally, gain of regions associated with the immune system and loss of regions involved in the apoptosis pathway were observed in cured patients suggesting a role of specific SCNA and corresponding altered pathways in the outcome of sporadic MTC.
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Francesco Barretta in
Google Scholar
PubMed
Search for other papers by Annalisa Trama in
Google Scholar
PubMed
Search for other papers by Laura Botta in
Google Scholar
PubMed
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Roberto Buzzoni in
Google Scholar
PubMed
University of Milan, Milan, Italy
Search for other papers by Filippo De Braud in
Google Scholar
PubMed
Liver Surgery, Transplantation and Gastroenterology, University of Milan and Istituto Nazionale Tumori Fondazione IRCCS, ENETS Center of Excellence, Milano, Milan, Italy
Search for other papers by Vincenzo Mazzaferro in
Google Scholar
PubMed
Search for other papers by Ugo Pastorino in
Google Scholar
PubMed
Search for other papers by Ettore Seregni in
Google Scholar
PubMed
Search for other papers by Luigi Mariani in
Google Scholar
PubMed
Search for other papers by Gemma Gatta in
Google Scholar
PubMed
Search for other papers by Maria Di Bartolomeo in
Google Scholar
PubMed
Search for other papers by Daniela Femia in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Jorgelina Coppa in
Google Scholar
PubMed
Search for other papers by Francesco Panzuto in
Google Scholar
PubMed
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Search for other papers by Maria Pia Brizzi in
Google Scholar
PubMed
Search for other papers by Davide Campana in
Google Scholar
PubMed
Search for other papers by Laura Catena in
Google Scholar
PubMed
Search for other papers by Harry Comber in
Google Scholar
PubMed
Search for other papers by Fiona Dwane in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Dario Giuffrida in
Google Scholar
PubMed
Search for other papers by Kris Henau in
Google Scholar
PubMed
Search for other papers by Toni Ibrahim in
Google Scholar
PubMed
Search for other papers by Riccardo Marconcini in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Maja Primic Žakelj in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Elizabeth Van Eycken in
Google Scholar
PubMed
Search for other papers by Jan Maaten Van der Zwan in
Google Scholar
PubMed
Search for other papers by Tina Žagar in
Google Scholar
PubMed
Search for other papers by Luca Giacomelli in
Google Scholar
PubMed
Search for other papers by Rosalba Miceli in
Google Scholar
PubMed
Search for other papers by NEPscore Working Group in
Google Scholar
PubMed
No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation sets, respectively. In conclusion, based on the analysis of three ‘field-practice’ cohorts collected in different settings, we defined and validated a prognostic score to classify patients into three groups with different long-term prognoses.
